|
|
|
|
|
|
|
|
 |
 |
 |
 |
 |
|
The average patient is older, heavier and has more airway issues putting them at greater risk of OSA. The real risk is that the majority are undiagnosed. The economic burden related to untreated OSA is substantial, accounting for billions of dollars per year. OSA patients are at greater risk of respiratory-related complications under inhaled anesthetics than non-OSA patients. The QED-100 is a new solution that removes volatile anesthetics from the OSA patient, significantly improving the safety and quality of their anesthetic experience. The QED-100 reverses volatile anesthetics by increasing cerebral blood flow and rapidly eliminating arterial anesthetic agent. The device quickly restores protective airway reflexes and increases the spontaneous drive to breathe, thereby reducing the risk of post-extubation aspiration, apnea and re-intubation. |
For a free trial of the
QED-100 for Sleep Apnea:
|
 |
 |
 |
||
EDUCATION |
TRAINING |
CLINICAL STUDIES |
||
Postoperative Complications in Surgical Patients at Risk for Obstructive Sleep Apnea, Kevin J. Finkel, et. al. Postoperative Complications in Patients with Obstructive Sleep Apnea, a Case-Control Study, Postoperative Events in Patients at Risk for OSA Undergoing Elective Surgery |
Using the QED-100: In-Service Training Video Dr. Derek Sakata demonstrates how to use the QED-100 in an actual case Using the QED-100 on Spontaneously-Breathing Patients Using the QED-100 with an LMA
|
John A. Moran Eye Center University of California San Francisco Hirosaki University Medical School, Japan |
||
 |
 |
 |
 |
 |
 |
